The effects of irbesartan on aortic dilatation in Marfan's syndrome

ISRCTN ISRCTN90011794
DOI https://doi.org/10.1186/ISRCTN90011794
Secondary identifying numbers 1
Submission date
12/02/2010
Registration date
06/04/2010
Last edited
16/12/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Michael Mullen
Scientific

Royal Brompton and Harefield NHS Foundation Trust
Sydney Street
London
SW3 6NP
United Kingdom

Phone +44 (0)20 7351 8600
Email m.mullen@rbht.nhs.uk

Study information

Study designProspective randomised placebo-controlled double-blind multi-centre trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleA prospective, randomised, placebo-controlled double blind, multicentre study of the effects of irbesartan on aortic dilatation in Marfan's syndrome
Study acronymAIMS
Study objectivesTo investigate the effects of irbesartan on aortic dilatation in Marfan's syndrome.
Ethics approval(s)UK Research Ethics Committee pending approval as of 12/02/2010.
Health condition(s) or problem(s) studiedMarfan's syndrome
Intervention1. Run in Phase: 75 mg open label irbesartan (1 month) - all patients
2. Month 2: 150 mg irbesartan/placebo once daily (o.d.)
3. Months 3 - 48: 300 mg irbesartan/placebo o.d.

The proposed target doses are 300 mg o.d. for patients greater than 50 kg and 150 mg o.d. for patients less than 50 kg. Maximum follow up will be 60 months.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase III
Drug / device / biological / vaccine name(s)Irbesartan
Primary outcome measureAbsolute change in aortic root diameter per year measured by echocardiography
Secondary outcome measures1. Change in z score per year - where the z score is calculated on aortic root and body surface area (BSA)
2. Clinical events and requirement for surgery including aortic dissection confirmed on transoesophageal echocardiography (TOE), magnetic resonance imaging (MRI) or computed tomography (CT)
3. Aortic dissection requiring emergency surgery
4. Aortic dissection requiring elective surgery
5. Aortic dilatation requiring elective or emergency surgery
6. Sudden death
7. Cerebrovascular accident
8. Cardiovascular death
9. Aortic regurgitation requiring surgery
10. Death during surgery for any of the above
11. Left ventricular function determined by volumes and ejection fraction
12. Left ventricular mass measurements
13. Assessment of valvular function
14. Cardiac rhythm and voltage
15. Height
16. Arm span and lower segment measurements
17. Fibrillin-1 mutation analysis will be performed in those patients whose mutation status is unknown

All outcomes are measured annually.
Overall study start date01/09/2010
Completion date03/03/2017

Eligibility

Participant type(s)Patient
Age groupOther
SexBoth
Target number of participants490
Total final enrolment192
Key inclusion criteria1. Clinically confirmed Marfan's syndrome
2. Aorta dilated above the normal 95th percentile
3. Greater than 6 and less than 40 years of age, either sex
4. Provision of informed consent
Key exclusion criteria1. Previous cardiac or aortic surgery
2. Planned cardiac or aortic surgery
3. Aortic diameter greater than or equal to 4.5 cm
4. Haemodynamically significant, severe valvular disease
5. Heart failure (defined as left ventricular ejection fraction [LVEF] less than 40%)
6. Therapeutic use of angiotensin converting enzyme (ACE) inhibitors/angiotensin-II receptor antagonist
7. Previous recorded adverse reaction to the trial medication (irbesartan)
8. Female patient who is pregnant, planning pregnancy or not using reliable contraception
9. Impaired renal function
Date of first enrolment01/09/2010
Date of final enrolment03/03/2017

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Royal Brompton and Harefield NHS Foundation Trust
London
SW3 6NP
United Kingdom

Sponsor information

Royal Brompton and Harefield NHS Foundation Trust (UK)
Hospital/treatment centre

Sydney Street
London
SW3 6NP
England
United Kingdom

Phone +44 (0)20 7351 8121
Email w.butcher@rbht.nhs.uk
Website http://www.rbht.nhs.uk
ROR logo "ROR" https://ror.org/02218z997

Funders

Funder type

Charity

British Heart Foundation (BHF) (UK)
Private sector organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
the_bhf, The British Heart Foundation, BHF
Location
United Kingdom
Marfan Trust (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 01/12/2013 Yes No
Results article results 21/12/2019 16/12/2019 Yes No

Editorial Notes

16/12/2019: Publication reference and total final enrolment number added.